Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment
Open Access
- 21 August 2014
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Immunology
- Vol. 10 (10), 1349-1356
- https://doi.org/10.1586/1744666x.2014.949675
Abstract
Biomarkers have great potential to improve the diagnosis and treatment of sepsis. The available literature supports the potential utility of sTREM-1, IL-27, suPAR, neutrophil CD64, presepsin, cfDNA and miRNAs as novel diagnostic, prognostic and treatment response biomarkers. The future of sepsis biomarkers lies in extensive validation studies of such novel biomarkers across heterogeneous populations and exploration of their power in combination. Furthermore, the use of a companion diagnostics model may augment the ability of investigators to identify novel sepsis biomarkers and develop specific therapeutic strategies based on biomarker information.Keywords
This publication has 53 references indexed in Scilit:
- Performance of interleukin-27 as a sepsis diagnostic biomarker in critically ill adultsJournal of Critical Care, 2014
- The Temporal Version of the Pediatric Sepsis Biomarker Risk ModelPLOS ONE, 2014
- Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trialCritical Care, 2014
- The pediatric sepsis biomarker risk modelCritical Care, 2012
- Neutrophil CD64 as a sepsis biomarkerBiochemia Medica, 2011
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patientsCritical Care, 2006
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- IL-27, a Heterodimeric Cytokine Composed of EBI3 and p28 Protein, Induces Proliferation of Naive CD4+ T CellsImmunity, 2002
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001